CMVLF Stock Chart & Stats
$3.47
$0.00(0.00%)
At close: 4:00 PM EDT
$3.47
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.95 - $5.04
Previous CloseN/A
Volume4.00
Average Volume (3M)946.00
Market Cap
$84.13M
Enterprise Value$205.35M
Total Cash (Recent Filing)$166.85M
Total Debt (Recent Filing)$84.57M
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
Nov 09, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding72,325,455
10 Day Avg. Volume2,840
30 Day Avg. Volume946
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market Cap2.44
Enterprise Value/Revenue3.63
Enterprise Value/Gross Profit4.86
Enterprise Value/Ebitda-4.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$52.08M
Bulls Say, Bears Say
Bulls Say
Allogeneic Therapy PlatformAn allogeneic, off-the-shelf approach could support broader and more scalable cell-therapy delivery than individualized treatments if clinical development succeeds. The combination of engineered T-cell research and associated manufacturing capabilities gives Cellectis an integrated platform for advancing multiple therapeutic programs.
Solid Gross MarginsA historically healthy gross margin indicates that the underlying technology, collaboration, or service activities can generate substantial value relative to direct costs. If revenue expands through partnerships or successful programs, this margin profile could provide operating leverage once development spending becomes better supported by revenue.
Demonstrated Cash-generation PotentialPositive operating and free cash flow in 2024 shows that Cellectis has previously been able to convert its activities into cash rather than relying exclusively on external funding. Although cash generation has since reverted to negative, this history indicates potential for improvement if collaboration receipts or operating performance strengthen.
Bears Say
Revenue ContractionDeclining TTM revenue weakens the near-term foundation for funding research and clinical development, particularly because Cellectis has limited recurring product sales and relies heavily on collaboration-related economics. Revenue volatility also makes it harder to plan investment and assess the pace at which the business can scale.
Deep Operating LossesThe scale of current losses shows that gross profit is not yet sufficient to absorb Cellectis's operating and development cost base. Persistently negative EBIT and EBITDA reduce internal funding capacity and make future financial performance highly dependent on successful clinical progress, partnerships, or eventual commercialization.
Cash Burn And Weaker Equity CushionLarge ongoing cash burn combined with a reduced equity cushion limits financial flexibility while the company remains clinical-stage. Higher debt relative to equity can increase pressure on future capital allocation and funding decisions, leaving less capacity to absorb delays or sustain development investment without additional financing.
Cellectis SA News
CMVLF FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $0.94 and its highest was $5.04 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $84.13M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Nov 09, 2026 which is in 9 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Aug 06, 2026. The company reported -$0.213 earnings per share for the quarter, beating the consensus estimate of -$0.254 by $0.041.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.17.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.213 in its last earnings report, beating expectations of -$0.254. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in CMVLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors